
## Srinivasulu Aitipamula

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1264405/publications.pdf Version: 2024-02-01



SDINIVASIILI AITIDAMIILA

#	Article	IF	CITATIONS
1	Polymorphs, Salts, and Cocrystals: What's in a Name?. Crystal Growth and Design, 2012, 12, 2147-2152.	3.0	767
2	Polymorphism in cocrystals: a review and assessment of its significance. CrystEngComm, 2014, 16, 3451.	2.6	242
3	Trimorphs of a pharmaceutical cocrystal involving two active pharmaceutical ingredients: potential relevance to combination drugs. CrystEngComm, 2009, 11, 1823-1827.	2.6	134
4	Polymorphs and Solvates of a Cocrystal Involving an Analgesic Drug, Ethenzamide, and 3,5-Dinitrobenzoic Acid. Crystal Growth and Design, 2010, 10, 2229-2238.	3.0	109
5	Halogen Trimer-Mediated Hexagonal Host Framework of 2,4,6-Tris(4-halophenoxy)-1,3,5-triazine. Supramolecular Isomerism from Hexagonal Channel (X = Cl, Br) to Cage Structure (X = I). Crystal Growth and Design, 2005, 5, 887-899.	3.0	98
6	Novel solid forms of the anti-tuberculosis drug, Isoniazid: ternary and polymorphic cocrystals. CrystEngComm, 2013, 15, 5877.	2.6	97
7	Guest-Induced Supramolecular Isomerism in Inclusion Complexes of T-Shaped Host 4,4-Bis(4′-hydroxyphenyl)cyclohexanone. Chemistry - A European Journal, 2005, 11, 6727-6742.	3.3	90
8	Polymorphs and Polymorphic Cocrystals of Temozolomide. Chemistry - an Asian Journal, 2008, 3, 1122-1133.	3.3	78
9	Dimorphs of a 1 : 1 cocrystal of ethenzamide and saccharin: solid-state grinding methods result in metastable polymorph. CrystEngComm, 2009, 11, 889.	2.6	73
10	Pharmaceutical cocrystals of ethenzamide: structural, solubility and dissolution studies. CrystEngComm, 2012, 14, 8515.	2.6	71
11	Conformational Polymorphism of Tolbutamide: A Structural, Spectroscopic, and Thermodynamic Characterization of Burger's Forms I–IV. Journal of Pharmaceutical Sciences, 2010, 99, 2975-2990.	3.3	62
12	Topological Equivalences between Organic and Coordination Polymer Crystal Structures:  An Organic Ladder Formed with Three-Connected Molecular and Supramolecular Synthons. Organic Letters, 2002, 4, 921-924.	4.6	61
13	Cocrystal Hydrate of an Antifungal Drug, Griseofulvin, with Promising Physicochemical Properties. Crystal Growth and Design, 2012, 12, 5858-5863.	3.0	61
14	Cocrystallization with flufenamic acid: comparison of physicochemical properties of two pharmaceutical cocrystals. CrystEngComm, 2014, 16, 5793.	2.6	60
15	Conformational and enantiotropic polymorphism of a 1 : 1 cocrystal involving ethenzamide and ethylmalonic acid. CrystEngComm, 2010, 12, 3691.	2.6	58
16	Multiple molecules in the crystallographic asymmetric unit. Self host–guest and doubly interpenetrated hydrogen bond networks in a pair of keto-bisphenols. CrystEngComm, 2003, 5, 447.	2.6	44
17	The solvates of sulfamerazine: structural, thermochemical, and desolvation studies. CrystEngComm, 2012, 14, 691-699.	2.6	44
18	Thermochemical Analysis of Venlafaxine Hydrochloride Polymorphs1â^'5â€. Crystal Growth and Design, 2005, 5, 2268-2276.	3.0	43

#	Article	IF	CITATIONS
19	Pharmaceutical Salts of Haloperidol with Some Carboxylic Acids and Artificial Sweeteners: Hydrate Formation, Polymorphism, and Physicochemical Properties. Crystal Growth and Design, 2014, 14, 2542-2556.	3.0	43
20	X-Ray Crystallography and its Role in Understanding the Physicochemical Properties of Pharmaceutical Cocrystals. Journal of the Indian Institute of Science, 2017, 97, 227-243.	1.9	42
21	Solvates and polymorphic phase transformations of 2-chloro-4-nitrobenzoic acid. CrystEngComm, 2011, 13, 1037-1045.	2.6	38
22	Co-crystals of caffeine and piracetam with 4-hydroxybenzoic acid: Unravelling the hidden hydrates of 1 : 1 co-crystals. CrystEngComm, 2012, 14, 2381.	2.6	36
23	Crystal Engineering of Tegafur Cocrystals: Structural Analysis and Physicochemical Properties. Crystal Growth and Design, 2014, 14, 6557-6569.	3.0	35
24	Design of Cocrystals for Molecules with Limited Hydrogen Bonding Functionalities: Propyphenazone as a Model System. Crystal Growth and Design, 2017, 17, 163-174.	3.0	35
25	Palladium Complexes with Bulky Diphosphine Ligands as Highly Selective Catalysts for the Synthesis of (Bio-) Adipic Acid from Pentenoic Acid Mixtures Organometallics, 2015, 34, 4281-4292.	2.3	33
26	Engineering the weak N–Hâ <ievic 2005,="" 4-tritylbenzamide="" 44-52.<="" 7,="" and="" bond="" controlling="" crystengcomm,="" guest="" host="" hydrogen="" in="" interaction="" selection.="" td="" the="" through=""><td>2.6</td><td>32</td></ievic>	2.6	32
27	Polymorphism and phase transformations of a cocrystal of nicotinamide and pimelic acid. CrystEngComm, 2012, 14, 8193.	2.6	30
28	Concomitant polymorphs of 2,2′,6,6′-tetramethyl-4,4′-terphenyldiol: the β-quinol network reproduced in a metastable polymorph. Chemical Communications, 2005, , 3159.	4.1	29
29	Novel solid forms of oxaprozin: cocrystals and an extended release drug–drug salt of salbutamol. RSC Advances, 2016, 6, 34110-34119.	3.6	28
30	Microsphaerins A–D, four novel benzophenone dimers with activity against MRSA from the fungus Microsphaeropsis sp Tetrahedron, 2008, 64, 10181-10187.	1.9	24
31	Conformational Polymorphs of a Muscle Relaxant, Metaxalone. Crystal Growth and Design, 2011, 11, 4101-4109.	3.0	24
32	Cocrystals of zonisamide: physicochemical characterization and sustained release solid forms. CrystEngComm, 2018, 20, 2923-2931.	2.6	24
33	Host–guest and network structures of some tetraphenylmethane derivatives. CrystEngComm, 2004, 6, 120-125.	2.6	23
34	Cocrystal formulations: A case study of topical formulations consisting of ferulic acid cocrystals. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 149, 95-104.	4.3	23
35	Evaluating Suspension Formulations of Theophylline Cocrystals With Artificial Sweeteners. Journal of Pharmaceutical Sciences, 2018, 107, 604-611.	3.3	21
36	Cocrystals of Leflunomide: Design, Structural, and Physicochemical Evaluation. Crystal Growth and Design, 2019, 19, 3923-3933.	3.0	19

Srinivasulu Aitipamula

#	Article	IF	CITATIONS
37	Hexagonal Host Framework of <i>sym</i> -Aryloxytriazines Stabilised by Weak Intermolecular Interactions. Molecular Crystals and Liquid Crystals, 2005, 440, 295-316.	0.9	17
38	Correction for Polymorphs, Salts and Cocrystals: What's in a Name?. Crystal Growth and Design, 2012, 12, 4290-4291.	3.0	17
39	Ladder and Hexagonal Hydrogen-bond Networks from a Self-complementary H-shaped Tecton. Supramolecular Chemistry, 2005, 17, 17-25.	1.2	14
40	Novel pharmaceutical cocrystals of triflusal: crystal engineering and physicochemical characterization. CrystEngComm, 2015, 17, 9323-9335.	2.6	14
41	Solvates of the antifungal drug griseofulvin: structural, thermochemical and conformational analysis. Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 2014, 70, 54-62.	1.1	12
42	Polymorphism and distinct physicochemical properties of the phloretin–nicotinamide cocrystal. CrystEngComm, 2022, 24, 560-570.	2.6	12
43	Structural, Spectroscopic and Thermal Analysis of Cocrystals of Carbamazepine and Piracetam with Hydroquinone. Journal of Chemical Crystallography, 2011, 41, 1604-1611.	1.1	11
44	Novel solid forms of lonidamine: crystal structures and physicochemical properties. CrystEngComm, 2017, 19, 2925-2935.	2.6	11
45	Ethenzamide–gentisic acid–acetic acid (2/1/1). Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o1045-o1046.	0.2	10
46	Cocrystal Formulations: Evaluation of the Impact of Excipients on Dissolution by Molecular Simulation and Experimental Approaches. Crystal Growth and Design, 2021, 21, 1006-1018.	3.0	10
47	Theophylline–gentisic acid (1/1). Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o2126-o2127.	0.2	9
48	<i>gem</i> -Dialkyl Effect in Diphosphine Ligands: Synthesis, Coordination Behavior, and Application in Pd-Catalyzed Hydroformylation. ACS Catalysis, 2020, 10, 663-671.	11.2	9
49	The amido-bridged zirconocene's reactivity and catalytic behavior for ethylenepolymerization. Dalton Transactions, 2010, 39, 807-814.	3.3	7
50	Solvates and a monohydrate of N4-acetylsulfamerazine: Structural, thermochemical, and computational analysis. Journal of Molecular Structure, 2011, 1005, 134-140.	3.6	7
51	Directing Selectivity to Aldehydes, Alcohols, or Esters with Diphobane Ligands in Pd-Catalyzed Alkene Carbonylations. Organometallics, 2021, 40, 1914-1925.	2.3	7
52	Hydrogen-bond networks in tris(4-hydroxyphenyl)methane and its 1:1 molecular complex with 4,4′-bipyridine. Acta Crystallographica Section C: Crystal Structure Communications, 2003, 59, o481-o484.	0.4	4
53	Agomelatine–hydroquinone (1:1) cocrystal: novel polymorphs and their thermodynamic relationship. Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 2019, 75, 969-977.	1.1	3
54	2-Aminopyridinium 1-phenylcyclopropane-1-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o3339-o3340.	0.2	2

#	Article	IF	CITATIONS
55	Pyrimidin-2-amine–1-phenylcyclopentane-1-carboxylic acid (1/1). Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o552-o553.	0.2	2
56	Polymorphism in Molecular Crystals and Cocrystals. , 2015, , 265-298.		2
57	1. Pharmaceutical co-crystals: crystal engineering and applications. , 2017, , 1-31.		1
58	Insights into the structure-property relationship of pharmaceutical co-crystals: Charge density and quantum chemical approaches. Journal of Molecular Structure, 2021, 1224, 129270.	3.6	1
59	N,N-Dimethylpyridin-4-aminium 1-phenylcyclopentane-1-carboxylate monohydrate. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o1227-o1227.	0.2	0
60	Synergistic enhancement of tabletability and physicochemical properties through co-crystallization. Acta Crystallographica Section A: Foundations and Advances, 2017, 73, C59-C59.	0.1	0
61	Reply to the â€~Comment on "Trimorphs of a pharmaceutical cocrystal involving two active pharmaceutical ingredients: potential relevance to combination drugs―by S. Aitipamula, P. S. Chow and R. B. H. Tan, <i>CrystEngComm</i> , 2009, <b>11</b> , 1823'. CrystEngComm, 2018, 20, 373-374.	2.6	0
62	Charge density studies on 1:1 co-crystals of ethenzamide and saccharin. Acta Crystallographica Section A: Foundations and Advances, 2014, 70, C964-C964.	0.1	0
63	Charge density studies on polymorphic co-crystals. Acta Crystallographica Section A: Foundations and Advances, 2015, 71, s415-s416.	0.1	0
64	Using charge density to understand structure–property relationships in pharmaceutical co-crystals. Acta Crystallographica Section A: Foundations and Advances, 2017, 73, C799-C799.	0.1	0